Skip to main content

Abstract

The International Congress of Pharmacology was held in Canada for the first time and one of the symposia was entitled “Interethnic Differences in Drug Metabolism and Pharmacogenetics”. The purpose of the symposium was to discuss genetic variation of drug metabolizing enzymes in different ethnic groups. Five speakers from Sweden, Japan, USA, Canada and U.K. participated in this symposium and discussed the pharmacogenetics of drug metabolism ranging from a molecular basis to some clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvan G. Genetic polymorphism in drug metabolism. J. Int. Med. 1992; 231: 571–573.

    Article  CAS  Google Scholar 

  2. Price Evans DA. Genetic factors in drug therapy — clinical and molecular pharmacogenetics. Cambridge: Cambridge University Press, 1993: 1–136.

    Google Scholar 

  3. Kalow W, Bertilsson L. Interethnic factors affecting drug response. In: Testa B, Meyer UA, editors. Advances in drug research. Vol. 25. London: Academic Press, 1994: 1–53.

    Google Scholar 

  4. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 1984; 26: 753–759.

    Article  PubMed  CAS  Google Scholar 

  5. Inaba T. Pharamcogenetic polymorphism: mephenytoin hydroxylation deficiency. In: Kato R, Estabrook RW, Cayen MN, (editors), Xenobiotic metabolism and disposition. London: Talor & Francis, 1989: 467–474.

    Google Scholar 

  6. Beischlag TV, Kalow W, Mahon WA, Inaba T. Diazepam metabolism by rat and human liver in vitro: inhibition by mephenytoin. Xenobiotica 1992; 22: 559–567.

    Article  PubMed  CAS  Google Scholar 

  7. Yasumori T, Li Q-H, Yamazoe Y, Ueda M, Tsuzuki T, Kato R. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics. 1994; 4: 323–331.

    Article  PubMed  CAS  Google Scholar 

  8. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major S-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743–1752.

    Article  PubMed  CAS  Google Scholar 

  9. de Morais SMF, Wilkinson GR, Blasidell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1984; 269: 15419–15422.

    Google Scholar 

  10. de Morais SMF, Wilkinson GR, Blasidell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994; 46: 594–598.

    PubMed  Google Scholar 

  11. Inaba T, Someya T, Shibasaki M, Tang SW, Takahashi S. Influence of ethnicity on reduced haloperidol concentrations in blood. In: Lin KM et al. (editors), Psychopharmacology and psychobiology of ethnicity. Washington: Am. Psychiatric Press, 1993: 123–132.

    Google Scholar 

  12. Someya T, Takahashi S, Shibasaki M, Inaba T, Cheung SW, Tang SW. Reduced haloperidol/haloperidol ratios: polymorphism in Japanese psychiatric patients. Psychiatry Res. 1990; 31: 111–120.

    Article  PubMed  CAS  Google Scholar 

  13. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengi JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 pheno-types in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116–127.

    Article  PubMed  CAS  Google Scholar 

  14. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW. Caffeine as a metabolic probe: A comparison of the metabolic ratios used to assess CYP1A2 activity. Brit. J. Clin. Pharmacol. In press.

    Google Scholar 

  15. Tucker GT, Rostami-Hodjegan A, Nurminen S, Jackson PR. (1994) In preparation.

    Google Scholar 

  16. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 1987; 42: 157–165.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Inaba, T. et al. (1995). Interethnic Differences in Drug Metabolism and Pharmacogenetics. In: Cuello, A.C., Collier, B. (eds) Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7218-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7218-8_17

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-0348-7220-1

  • Online ISBN: 978-3-0348-7218-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics